
Page#1
Table of Contents
Item 8. Financial Statements and Supplementary Data.
(a) Financial Statements
The consolidated balance sheet of Merck & Co., Inc. and subsidiaries as of December 31, 2018 and 2017, and
the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the
three years in the period ended December 31, 2018, the notes to consolidated financial statements, and the report dated
February 27, 2019 of PricewaterhouseCoopers LLP, independent registered public accounting firm, are as follows:
Consolidated Statement of Income
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions except per share amounts)
2018 2017 2016
Sales $ 42,294 $ 40,122 $ 39,807
Costs, Expenses and Other
Cost of sales 13,509 12,912 14,030
Selling, general and administrative 10,102 10,074 10,017
Research and development 9,752 10,339 10,261
Restructuring costs 632 776 651
Other (income) expense, net (402) (500) 189
33,593 33,601 35,148
Income Before Taxes 8,701 6,521 4,659
Taxes on Income 2,508 4,103 718
Net Income 6,193 2,418 3,941
Less: Net (Loss) Income Attributable to Noncontrolling Interests (27) 24 21
Net Income Attributable to Merck & Co., Inc. $ 6,220 $ 2,394 $ 3,920
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common
Shareholders $ 2.34 $ 0.88 $ 1.42
Earnings per Common Share Assuming Dilution Attributable to Merck & Co.,
Inc. Common Shareholders $ 2.32 $ 0.87 $ 1.41
Consolidated Statement of Comprehensive Income
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions)
2018 2017 2016
Net Income Attributable to Merck & Co., Inc. $ 6,220 $ 2,394 $ 3,920
Other Comprehensive (Loss) Income Net of Taxes:
Net unrealized gain (loss) on derivatives, net of reclassifications 297 (446) (66)
Net unrealized loss on investments, net of reclassifications (10) (58) (44)
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization (425) 419 (799)
Cumulative translation adjustment (223) 401 (169)
(361) 316 (1,078)
Comprehensive Income Attributable to Merck & Co., Inc. $ 5,859 $ 2,710 $ 2,842
The accompanying notes are an integral part of these consolidated financial statements.
68
Page#2
Table of Contents
Consolidated Balance Sheet
Merck & Co., Inc. and Subsidiaries
December 31
($ in millions except per share amounts)
2018 2017
Assets
Current Assets
Cash and cash equivalents $ 7,965 $ 6,092
Short-term investments 899 2,406
Accounts receivable (net of allowance for doubtful accounts of $119 in 2018
7,071 6,873
and $159 in 2017) 
Inventories (excludes inventories of $1,417 in 2018 and $1,187 in 2017
5,440 5,096
classified in Other assets - see Note 7)
Other current assets 4,500 4,299
Total current assets 25,875 24,766
Investments 6,233 12,125
Property, Plant and Equipment (at cost)
Land 333 365
Buildings 11,486 11,726
Machinery, equipment and office furnishings 14,441 14,649
Construction in progress 3,355 2,301
29,615 29,041
Less: accumulated depreciation 16,324 16,602
13,291 12,439
Goodwill 18,253 18,284
Other Intangibles, Net 11,431 14,183
Other Assets 7,554 6,075
$ 82,637 $ 87,872
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt $ 5,308 $ 3,057
Trade accounts payable 3,318 3,102
Accrued and other current liabilities 10,151 10,427
Income taxes payable 1,971 708
Dividends payable 1,458 1,320
Total current liabilities 22,206 18,614
Long-Term Debt 19,806 21,353
Deferred Income Taxes 1,702 2,219
Other Noncurrent Liabilities 12,041 11,117
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
1,788 1,788
Issued - 3,577,103,522 shares in 2018 and 2017
Other paid-in capital 38,808 39,902
Retained earnings 42,579 41,350
Accumulated other comprehensive loss (5,545) (4,910)
77,630 78,130
Less treasury stock, at cost:
50,929 43,794
984,543,979 shares in 2018 and 880,491,914 shares in 2017
Total Merck & Co., Inc. stockholders’ equity 26,701 34,336
Noncontrolling Interests 181 233
Total equity 26,882 34,569
$ 82,637 $ 87,872
The accompanying notes are an integral part of this consolidated financial statement.
69
Page#3
Table of Contents
Consolidated Statement of Cash Flows
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions)
2018 2017 2016
Cash Flows from Operating Activities
Net income $ 6,193 $ 2,418 $ 3,941
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 4,519 4,676 5,471
Intangible asset impairment charges 296 646 3,948
Charge for future payments related to collaboration license options 650 500 —
Provisional charge for one-time transition tax related to the enactment of U.S. tax
legislation — 5,347 —
Charge related to the settlement of worldwide Keytruda patent litigation — — 625
Deferred income taxes (509) (2,621) (1,521)
Share-based compensation 348 312 300
Other 978 190 213
Net changes in assets and liabilities:
Accounts receivable (418) 297 (619)
Inventories (911) (145) 206
Trade accounts payable 230 254 278
Accrued and other current liabilities (341) (922) (2,018)
Income taxes payable 827 (3,291) 124
Noncurrent liabilities (266) (123) (809)
Other (674) (1,087) 237
Net Cash Provided by Operating Activities 10,922 6,451 10,376
Cash Flows from Investing Activities
Capital expenditures (2,615) (1,888) (1,614)
Purchases of securities and other investments (7,994) (10,739) (15,651)
Proceeds from sales of securities and other investments 15,252 15,664 14,353
Acquisitions, net of cash acquired (431) (396) (780)
Other 102 38 482
Net Cash Provided by (Used in) Investing Activities 4,314 2,679 (3,210)
Cash Flows from Financing Activities
Net change in short-term borrowings 5,124 (26) —
Payments on debt (4,287) (1,103) (2,386)
Proceeds from issuance of debt — — 1,079
Purchases of treasury stock (9,091) (4,014) (3,434)
Dividends paid to stockholders (5,172) (5,167) (5,124)
Proceeds from exercise of stock options 591 499 939
Other (325) (195) (118)
Net Cash Used in Financing Activities (13,160) (10,006) (9,044)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash (205) 457 (131)
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash 1,871 (419) (2,009)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $4 million of
6,096 6,515 8,524
restricted cash at January 1, 2018 included in Other Assets)
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $2 million of
$ 7,967 $ 6,096 $ 6,515
restricted cash at December 31, 2018 included in Other Assets)
The accompanying notes are an integral part of this consolidated financial statement.
71